Verdezyne, Inc., a privately-held industrial biotechnology company focused on
producing renewable chemicals, announced the sale of its proprietary xylose
isomerase technology, enabling the metabolism of 5-carbon sugars, to DuPont
Industrial Biosciences, a world leader in science and innovation.
Under the terms of the sale, DuPont has purchased rights to Verdezyne's
patented xylose isomerase technology, covered by U.S. Patent Nos. 8,114,974
and 8,093,037, for use in the rapidly-commercializing biofuels and biochemical
fields. This technology allows the fast and complete utilization of
biomass-sourced C5 sugars in production of various products of choice. This
technological breakthrough was highlighted in a recent Journal of Industrial
Microbiology & Biotechnology article published August 2012.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in